Cardinal Health — Jan 30, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000721371-25-000009
Showing in the filing
Interest and other expense
“$200 million to $230 million”
Period
FY2025
Measure
GAAP-tied
Source
Prose
All guidance in this release · 6
Non-GAAP diluted earnings per share attribut… for FY2025
“$7.85 to $8.00”
Non-GAAP diluted EPS for FY2025
“$7.85 to $8.00”
Pharmaceutical and Specialty Solutions segme… for FY2025
“10% to 12% growth”
Global Medical Products and Distribution seg… for FY2025
“$130 million to $150 million”
GMPD segment profit for FY2025
“$130 million to $150 million”
Interest and other expense for FY2025
“$200 million to $230 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
The company also updated its GMPD fiscal 2025 segment profit guidance to a range of $130 million to $150 million from the prior range of $140 million to $175 million, primarily reflecting the second-quarter write-off of uncollectible receivables in the WaveMark business. The company updated expectations for interest and other expense to a range of $200 million to $230 million, from $140 million to $170 million, driven by the advanced completion of $2.9 billion in new debt financing and foregone interest income related to acquisitions. Recent highlights • Cardinal Health today announced the completion of its acquisition of a majority stake in GI Alliance. With over 900 physicians across 345 practice locations in 20 states, GI Alliance is the country’s leading gastroenterology management services organization (MSO). The acquisition accelerates Cardinal Health’s multi-specialty growth strategy. • Cardinal Health completed its acquisition of Integrated Oncology Network in December. ION is a physician-led independent community oncology network that accelerates the development of Navista oncology alliance, providing additional capabilities supporting independent community practices and adding more than 100 providers delivering broad-reaching oncology and urology care across 10 states. • Cardinal Health announced the start of routine production of actinium-225 (Ac-225) through its Center for Theranostics Advancement in collaboration with TerraPower Isotopes. Cardinal Health is the first company to offer the isotope at commercial scale, increasing access to th
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.